Bionic Biologics for better medicines
Grove Biopharma is pioneering Bionic Biologics™, a breakthrough synthetic modality for developing novel therapeutics that target intracellular protein-protein interactions.
Bionic Biologics
Bionic
Hybrid biomolecules that integrate principles of biologic and synthetic design, resulting in enhanced functionality beyond what is possible in nature
Cell permeable
Multivalent, chameleonic architecture enables membrane permeability to reach intracellular targets
Customizable
Plug-and-play design, modular construction, and tunable properties to rapidly design and develop molecules - either monofunctional or bispecific - against any target
Getting biologics into cells will give patients better options
At Grove Biopharma, we’re striving for better medicines for patients living with cancer, neurodegenerative diseases, and rare disorders.
Proteins are the molecular machines that drive all essential cellular functions. Dysregulated intracellular protein-protein interactions (PPIs) are at the core of most devastating human diseases – but current modalities are either unable to penetrate cells or cannot effectively engage large PPI target domains.
We provide protein-scale solutions to protein-scale problems. Our Bionic Biologics platform generates synthetic biologics that can penetrate cells, to disrupt or degrade disease-causing target proteins.
Bionic Biologics have demonstrated proof-of-concept across several validated yet formidable intracellular targets
Breakthrough synthetic chemistry, made in Chicago
Grove Biopharma is a multidisciplinary team of chemists, biologists, materials scientists, and entrepreneurs working together to advance a new synthetic drug modality with transformative potential for patients.
We are based in the heart of Chicago and proud to contribute to the city’s emerging life sciences ecosystem.
